The new test aids health care professionals and patients in determining whether a specific medication will address ADHD symptoms effectively.
A Tennessee-based genetic testing company has launched a new genetic test that aids health care professionals and attention deficit hyperactivity disorder (ADHD) patients in determining whether a specific medication will address ADHD symptoms effectively.
Available for purchase from a pharmacy for less than $100, Harmonyx’s swab test examines the effects of 4 genes on ADHD patients’ metabolisms, as well as the efficacy of 21 different ADHD medications, including Adderall, Vyvanse, and Ritalin. Once the laboratory receives the test, detailed results with guidance on ADHD therapy are returned to the pharmacist and physician in as little as 24 hours.
“We are seeing all too often a trial-and-error approach to the prescription process. This is a slow and inadequate way to help those diagnosed with ADHD get the effective treatment they need,” said Bob Bean, president and chief executive officer of Harmonyx, in a press release. “Our affordable new test gives caregivers, parents and patients the ability to make informed decisions about the medications they choose.”
The test was designed to help ADHD patients who have not responded well to initial therapies and would like to seek alternative options. Harmonyx noted that it could be especially valuable to those with a recent ADHD diagnosis or current ineffective treatment.